Spiros Fourlanos

Increased Hyperglycemia and Hospital-Acquired Infections Following Withdrawal of the RAPIDS Early Intervention Model of Diabetes Care in Medical and Surgical Inpatients.

Mervyn Kyi, Joanna Wang, Spiros Fourlanos

Journal article  |  2020  |  Diabetes Care

Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.

Ralley E Prentice, Doug Tjandra, Mayur Garg, John S Lubel, Spiros Fourlanos, Doug Johnson, Aysha Al-Ani, Britt Christensen

Journal article  |  2020  |  Alimentary Pharmacology and Therapeutics

Nursing perceptions of the importance of blood glucose monitoring in hospital wards

RD Barmanray, LM Rowan, J Tsan, AE Dodds, K Long, D Heinjus, M Kyi, S Fourlanos

Journal article  |  2020  |  British Journal of Healthcare Management

Background/Aims Diabetes mellitus is increasingly prevalent among hospital inpatients. Management requires regular blood glucose m..

Routine glucose assessment in the emergency department for detecting unrecognised diabetes: a cluster randomised trial

Spiros Fourlanos, Rahul Barmanray, Mervyn Kyi

Journal article  |  2020  |  The Medical Journal of Australia

Clinical Prediction Tool To Identify Adults With Type 2 Diabetes at Risk for Persistent Adverse Glycemia in Hospital.

Mervyn Kyi, Alexandra Gorelik, Jane Reid, Lois M Rowan, Paul R Wraight, Peter G Colman, Spiros Fourlanos

Journal article  |  2020  |  Canadian Journal of Diabetes

OBJECTIVES: Given the high incidence of hyperglycemia and hypoglycemia in hospital and the lack of prediction tools for this probl..

A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetes.

John M Wentworth, Spiros Fourlanos, Peter G Colman, Leonard C Harrison

Journal article  |  2020  |  Metabol Open

Introduction: Sodium-glucose linked transporter (SGLT) inhibitors could improve glycaemia and simplify insulin regimens in recent-..

Factors that predict glycaemic response to sodium-glucose linked transporter (SGLT) inhibitors.

Amy L Harding, Naiara Bediaga, Anna Galligan, Peter G Colman, Spiros Fourlanos, John M Wentworth

Journal article  |  2020  |  Internal Medicine Journal

AIM: This study aimed to determine the clinical and biochemical variables associated with change in HbA1c in patients with type 2 ..

SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission

Peter S Hamblin, Rosemary Wong, Elif Ekinci, Spiros Fourlanos, Sonali Shah, Alicia R Jones, Matthew JL Hare, Genevieve L Calder, Dilan Seneviratne Epa, Elizabeth M George, Rinky Giri, Mark A Kotowicz, Mervyn Kyi, Nicole Lafontaine, Richard J MacIsaac, Brendan J Nolan, David N O'Neal, Debra Renouf, Suresh Varadarajan, Jennifer Wong, et al.

Journal article  |  2019  |  The Journal of Clinical Endocrinology & Metabolism

CONTEXT: Diabetic ketoacidosis (DKA) has been associated with the use of sodium glucose cotransporter 2 inhibitors (SGLT2is). OBJE..

Glucometric benchmarking in an Australian hospital enabled by networked glucose meter technology

Mervyn Kyi, Peter G Colman, Lois M Rowan, Katie A Marley, Paul R Wraight, Spiros Fourlanos

Journal article  |  2019  |  The Medical Journal of Australia

OBJECTIVE: To assess glucometric outcomes and to estimate the incidence of hypo- and hyperglycaemia among non-critical care inpati..

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén, Denis Xavier, Charles Messan Atisso, Leanne Dyal, Stephanie Hall, Purnima Rao-Melacini, Gloria Wong, Alvaro Avezum, Jan Basile, Namsik Chung, Ignacio Conget, et al.

Journal article  |  2019  |  The Lancet

BACKGROUND: Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2..